21 Adult ependymoma in England: Incidence, treatment, and outcomes from GlioCova

Clicks: 15
ID: 326804
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #229 of 286 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 286 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction England has a long-running system for national cancer data collection. In this work we present data on incidence, treatment and survival in all adult ependymoma patients in England diagnosed between 2013 and 2018. Methods Gliocova uses a linked pseudo-anonymised data set of all adult patients in England diagnosed with a primary brain tumour between 2013 and 2018. We identified all adult patients with an ependymoma based on ICD-10 diagnosis and tumour morphology. Results In the 6-year period of the study (2013-2018 inclusive), 512 patients were diagnosed with an ependymoma in England: (G1: 14 patients; G2: 486; G3: 12). The commonest entity was G2 ependymoma of the spinal cord (304 patients). The national age-standardised incidence was 0.16 adult ependymoma patients per 100,000 per year. Overall, 86% of patients received treatment (87% female vs. 85% male, p = 0.32) with most patients (84%) undergoing either major resection and/or biopsy and 23% also received radiotherapy. Median survival for patients with G3 ependymoma was 26 months. Five-year survival for patients with G2 ependymoma was 82% but only 48% for those with a G3. In this cohort, 14% of patients died, mainly in hospital (57%). Conclusion This is the first national study looking at adult patients diagnosed with ependymomas in England. Ependymoma is very rare, at 3% of the incidence of GBM. Almost 90% of patients received treatment, mainly surgery. Further work will explore patients’ inpatient admissions, the frequency of these, and the length of stay. This work highlights the rarity of ependymoma, and the need for national-level data and research.
Reference Key
openalex_W7204479983 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kerlann Le Calvez, Radvile Mauricaite, Peter Treasure, Thomas C. Booth, Stephen J. Price, A. Brodbelt, Jonathan J Gregory, Seema Dadhania, Lillie Pakzad-Shahabi, Maureen Dumba, Ingela Oberg, Sally Vernon, Jawad Basharat, Matt Williams
Are you one of these authors? Claim your profile
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag172.012
URL
https://academic.oup.com/neuro-oncology/article-pdf/28/Supplement_1/noag172.012/70805907/noag172.012.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.